Suppr超能文献

处方精神药物对青少年的影响。

The impact of prescribed psychotropics on youth.

作者信息

Lakhan Shaheen E, Hagger-Johnson Gareth E

机构信息

Global Neuroscience Initiative Foundation, Los Angeles, CA, USA.

出版信息

Clin Pract Epidemiol Ment Health. 2007 Oct 20;3:21. doi: 10.1186/1745-0179-3-21.

Abstract

Many psychotropics prescribed to children are unlicensed or off-label. This article uses the two most prescribed psychotropics (MPH and SSRIs) to illustrate various concerns about their impact on youth. Many mental illnesses begin in childhood or early adulthood, warranting a treatment of some kind. However, commentators have argued that prescribing is influenced by five myths: (1) children are little adults; (2) children have no reason to develop depression or anxiety; (3) psychiatric disorders are the same across adults and children; (3) children can be prescribed lower doses of the same drug; (5) drugs are preferable to alternative treatments and are more successful. Several lines of evidence suggest that these are incorrect assumptions. We update readers with recent research in relation to these myths, concluding that researchers should clarify child/adult differences for psychotropics, attend to the growth of "cosmetic" use of psychotropics in children and adolescents, and address concerns about the diagnostic validity of mental illness in the current DSM classification system.

摘要

许多开给儿童的精神药物是未获许可的或标签外使用的。本文使用两种最常开具的精神药物(哌甲酯和选择性5-羟色胺再摄取抑制剂)来说明对它们对青少年影响的各种担忧。许多精神疾病始于童年或成年早期,需要某种治疗。然而,评论者认为,开药受到五个误区的影响:(1)儿童是小大人;(2)儿童没有理由患上抑郁症或焦虑症;(3)成人和儿童的精神疾病是一样的;(4)儿童可以开较低剂量的同一种药物;(5)药物比替代治疗更可取且更有效。几条证据表明这些是错误的假设。我们向读者介绍与这些误区相关的最新研究,得出结论:研究人员应阐明精神药物在儿童/成人之间的差异,关注儿童和青少年中精神药物“美容性”使用的增长情况,并解决对当前《精神疾病诊断与统计手册》分类系统中精神疾病诊断有效性的担忧。

相似文献

1
The impact of prescribed psychotropics on youth.
Clin Pract Epidemiol Ment Health. 2007 Oct 20;3:21. doi: 10.1186/1745-0179-3-21.
2
A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness.
J Intellect Disabil Res. 2005 Nov;49(Pt 11):858-64. doi: 10.1111/j.1365-2788.2005.00723.x.
3
BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents.
J Psychopharmacol. 2016 May;30(5):416-21. doi: 10.1177/0269881116636107.
7
Clinical setting influences off-label and unlicensed prescribing in a paediatric teaching hospital.
PLoS One. 2015 Mar 10;10(3):e0120630. doi: 10.1371/journal.pone.0120630. eCollection 2015.
9
Cross-sectional survey of off-label and unlicensed prescribing for inpatients at a paediatric teaching hospital in Western Australia.
PLoS One. 2019 Jan 8;14(1):e0210237. doi: 10.1371/journal.pone.0210237. eCollection 2019.
10
Off-label and unlicensed utilisation of medicines in a French paediatric hospital.
Int J Clin Pharm. 2015 Dec;37(6):1222-7. doi: 10.1007/s11096-015-0191-3. Epub 2015 Sep 22.

引用本文的文献

1
Uses of psychotropic drugs by university students in Switzerland.
PLoS One. 2024 Jun 13;19(6):e0305392. doi: 10.1371/journal.pone.0305392. eCollection 2024.
2
Building up bit by bit, parent's experiences of equine-assisted intervention among children and adolescents with mental illness: a grounded theory study.
Int J Qual Stud Health Well-being. 2024 Dec;19(1):2354945. doi: 10.1080/17482631.2024.2354945. Epub 2024 May 17.
3
Mental Health-Related Outpatient Visits Among Adolescents and Young Adults, 2006-2019.
JAMA Netw Open. 2024 Mar 4;7(3):e241468. doi: 10.1001/jamanetworkopen.2024.1468.
4
Prescription Psychoactive Medication Use in Adolescent Survivors of Childhood Cancer and Association With Adult Functional Outcomes.
JNCI Cancer Spectr. 2020 Jun 29;4(5):pkaa057. doi: 10.1093/jncics/pkaa057. eCollection 2020 Oct.
5
Trends in psychiatric disorders prevalence and prescription patterns of children in Alberta, Canada.
Soc Psychiatry Psychiatr Epidemiol. 2019 Dec;54(12):1565-1574. doi: 10.1007/s00127-019-01714-w. Epub 2019 May 25.
6
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.
J Child Adolesc Psychopharmacol. 2018 Sep;28(7):437-444. doi: 10.1089/cap.2018.0030. Epub 2018 Jul 13.
7
From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.
Curr Neuropharmacol. 2016;14(1):17-27. doi: 10.2174/1570159x13666150407225902.

本文引用的文献

2
Axis I and II comorbidity in adults with ADHD.
J Abnorm Psychol. 2007 Aug;116(3):519-28. doi: 10.1037/0021-843X.116.3.519.
3
6
Ethical issues in child psychopharmacology research and practice: emphasis on preschoolers.
Psychopharmacology (Berl). 2007 Mar;191(1):15-26. doi: 10.1007/s00213-006-0685-8. Epub 2007 Feb 6.
8
Safety and tolerability of methylphenidate in preschool children with ADHD.
J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1294-1303. doi: 10.1097/01.chi.0000235082.63156.27.
9
Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS).
J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1275-1283. doi: 10.1097/01.chi.0000235074.86919.dc.
10
Stimulant-related reductions of growth rates in the PATS.
J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1304-1313. doi: 10.1097/01.chi.0000235075.25038.5a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验